Table 24e. Drug Interactions Between the CCR5 Antagonist Maraviroc and Other Drugs (Including Antiretroviral Agents) In the table below, “no dose adjustment needed” indicates that the U.S. Food and Drug Administration–approved dose of maraviroc (MVC) 300 mg twice daily should be used. Recommendations for managing a particular drug interaction may differ, depending on whether a …
Table 24f. Drug Interactions Between HIV-1 gp120-Directed Attachment Inhibitors and Other Drugs (Including Antiretroviral Agents) Fostemsavir (FTR), an HIV-1 gp120-directed attachment inhibitor, is a prodrug of temsavir (TMR). In this table, the effect on gp120-directed attachment inhibitor refers to TMR concentrations. Recommendations for managing a particular drug interaction may differ depending on whether a new …
Table 25a. Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors Note: Interactions associated with DLV, FPV, IDV, NFV, TPV, and SQV are not included in this table. Please refer to the Food and Drug Administration product labels for information regarding interactions between these drugs and other concomitant drugs. Rilpivirine (RPV) intramuscular (IM) is not included in this …
AU Comment: INSTI and NNRTI regimen switches INSTI metabolism via CYP3A4, concurrent use with inducers results in diminished INSTI plasma concentration – advise caution when switching from NNRTI-based to INSTI-based ART regimens due to NNRTI half-life and resolution of induction effect AU Comment: Etravirine and cobicistat boosted Integrase regimens Etravirine (ETR) is not recommended in …
This section has information on Limitations to Treatment Safety & Efficacy. Please click on the below links or follow the table of contents to access the information you are looking for. Cost Considerations and ART Adherence to the Continuum of Care Adverse Effects of ARV Agents
AU Comment: Australian data on rates of virological suppression Data from the 2022 Annual Surveillance Report estimates at the end of 2021, there were 29 460 people living with HIV in Australia. Of these an estimated 91% (26 830) had been diagnosed. Of those diagnosed at the end of 2021, an estimated 96% (25 820) …
AU Comment: Weight gain and INSTIs Several reports have identified associations between the use of integrase strand transfer inhibitors (INSTIs) and increased weight and/or body mass index (BMI). It is unclear if this is a causal relationship or is associated with increased morbidity from conditions typically associated with increased weight such as type 2 diabetes …
AU Comment: Cost considerations and ART in the Australian context The Australian Government provides fully subsidised ARV drugs under the Highly Specialised Drugs (HSD) Program. To gain access to a Commonwealth funded drug under this program, a patient must be an Australian resident in Australia (or other eligible person) and have a Medicare card. Patients …
This section has information on Considerations for Antiretroviral Use in Patients with Coinfections. Please click on the below links or follow the table of contents to access the information you are looking for. TB/HIV HBV/HIV HCV/HIV
AU Comment: Australian epidemiology Approximately 5% of Australia’s 26,500 people with HIV also have chronic hepatitis B. Reference: GESA Australian consensus recommendations for the management of hepatitis B infection Panel’s Recommendations Regarding Hepatitis B Virus/ HIV Coinfection Panel’s Recommendations Before initiation of antiretroviral therapy (ART), all patients who test positive for hepatitis B surface antigen …
Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce
Acknowledgement of Country
We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.
ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM